预约演示
更新于：2025-07-23
Rebamipide
雷巴米特
更新于：2025-07-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
143
项与 雷巴米特 相关的临床试验CTR20243901
健康受试者空腹和餐后状态下单次口服瑞巴派特片的随机、开放、两序列、两制剂、两周期、双交叉设计的生物等效性试验
CTR20242604
瑞巴派特片采用单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计，分为空腹给药和餐后给药的人体生物等效性研究。
CTR20240809
健康受试者单次口服瑞巴派特片的随机、开放、两周期、两序列、双交叉，空腹和高脂餐后给药条件下的人体生物等效性试验。
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
969
项与 雷巴米特 相关的文献（医药）2025-08-01INTERNATIONAL JOURNAL OF MASS SPECTROMETRY
Miniature APCI ion source using AC corona discharge in a PFA tube: its application to the analysis of low-volatility compounds coupled with heat pulse desorption mass spectrometry (HPD/MS)
作者: Kinoshita, Kazumasa ; Shimada, Haruo ; Ninomiya, Satoshi ; Hiraoka, Kenzo ; Rankin-Turner, Stephanie
DC corona discharge has long been used as the APCI ion source.In 2013, Habib et al. first proposed AC corona discharge as an APCI ion source and found that it is superior to DC as an ambient ion source [1].In this study, an ion source using AC corona enclosed in a PFA (perfluoroalkoxy) tube (i.d.: 2 mm) was developed as a miniature APCI ion source coupled with heat pulse desorption mass spectrometry (HPD-MS) and used for the desorption of low-volatility compoundsDiverse materials were introduced, demonstrating the potential to apply the miniature ion source to gas-phase analytes, liquid samples, and solid materials in their native state.The modified technique was utilized in the anal. of a range of samples, including solid and liquid pharmaceuticals, food products, plant material, insects, and human biofluids, highlighting the wide applicability of the miniature APCI ion source across diverse sample types and fields of study.
2025-07-01GLOBAL CHALLENGES
Dry Eye Disease: Oxidative Stress on Ocular Surface and Cutting‐Edge Antioxidants
Review
作者: Xie, Can‐Ming ; Hu, Rong ; Shi, Jian ; Yao, Xiao‐Lei
Abstract:
Dry eye disease (DED), a multifactorial ocular surface disorder characterized by tear film instability, is pathologically linked to oxidative damage. The accumulation of reactive oxygen species (ROS) across ocular tissues not only directly damages nucleic acids, proteins, and lipids, but also functions as an upstream driver of inflammation and tear hyperosmolarity, collectively disrupting cellular homeostasis. This review comprehensively delineates the mechanistic interplay between oxidative stress (OS) and DED pathogenesis, synthesizing evidence on enzymatic/ nonenzymatic antioxidant alterations in samples of corneal, lacrimal, conjunctival, meibomian gland, and tear tissues, alongside quantitative profiling of OS biomarkers, such as 4‐hydroxynonenal (4HNE), malondialdehyde (MDA), 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG), and 3‐nitrotyrosine (3‐NT). Furthermore, the therapeutic mechanisms of clinically approved and investigational antioxidants, including SKQ1, rebamipide, mitoquinone, elamipretide, lactoferrin, nanozymes, graphene quantum dots, tetrahedral frame of nucleic acids, and Chinese medicine monomers are critically evaluated. With the changes in the modern social environment and lifestyle, the influence of OS on DED is gradually expanding. Antioxidant‐based interventions are poised to become cornerstone components of multimodal DED management strategies.
2025-06-01Cureus Journal of Medical Science
Comparative Efficacy of Treatments for Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer.
Review
作者: Patel, Raj ; Patel, Jay ; Masys, Tadas ; Amor, Shareef
Radiation-induced oral mucositis is a common and painful side effect in patients with head and neck cancer undergoing radiation therapy, causing inflammation and ulceration of the oral mucosa. This condition severely impacts a patient's ability to eat, speak, or swallow, making effective prevention crucial for improving quality of life. This review aimed to evaluate and compare treatments for radiation-induced oral mucositis, focusing on symptom relief and side effects. We included studies with clear outcome measures, pre- and post-treatment scores, and demographic data, excluding case reports, reviews, and abstracts. Our literature search through PubMed and the Excerpta Medica Database (EMBASE) identified 190 articles, which were narrowed down to nine after abstract analysis. From the systematic review findings, omega-3 nanoemulgel demonstrated the lowest complication rate (2.9%), with minimal impact on symptoms, making it the most effective treatment. In contrast, rebamipide and benzydamine had higher complication rates (25% and 28%, respectively) and less significant symptom relief. Given its safety, efficacy, and minimal side effects, omega-3 nanoemulgel should be considered a first-line preventive treatment for oral mucositis in patients with head and neck cancer.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 申请上市 | 韩国 | - | |
| 急性胃炎 | 临床3期 | 美国 | 2019-12-30 | |
| 强直性脊柱炎 | 临床3期 | 美国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 美国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 美国 | 2007-12-01 | |
| 毒性 | 临床3期 | 美国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新冠肺炎后遗症 CRP | 62 | 廠鬱積淵鑰醖選艱獵蓋(夢鏇襯糧願觸餘憲鑰觸) = 鹹壓淵衊膚廠艱製壓遞 淵鏇觸築淵積簾壓遞選 (遞襯膚艱築網鹹網鹽繭, [1.85 ~ 2.62]) | 积极 | 2024-02-23 | ||
廠鬱積淵鑰醖選艱獵蓋(夢鏇襯糧願觸餘憲鑰觸) = 鬱憲襯鏇網廠顧蓋範膚 淵鏇觸築淵積簾壓遞選 (遞襯膚艱築網鹹網鹽繭, [2.68 ~ 3.9]) | |||||||
临床2期 | 124 | (Rebamipide 60 mg) | 夢淵憲簾願醖餘艱觸鏇 = 顧鹹憲壓糧膚鑰壓壓觸 顧襯構餘構淵膚蓋夢廠 (製選遞膚蓋顧觸衊簾簾, 鏇鬱鬱選鏇齋網窪網艱 ~ 鏇簾蓋膚憲膚夢積淵鏇) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 夢淵憲簾願醖餘艱觸鏇 = 艱築廠鹽鏇蓋遞蓋積範 顧襯構餘構淵膚蓋夢廠 (製選遞膚蓋顧觸衊簾簾, 膚膚膚糧鏇醖遞衊築齋 ~ 築鹽淵鹹鏇蓋膚夢網鑰) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 醖顧糧獵齋淵願衊築築 = 願鑰鏇鬱構窪糧簾製艱 遞淵夢鏇鹽遞齋淵簾獵 (顧壓膚觸艱觸願襯襯憲, 餘襯簾觸糧鹹鏇鏇鑰襯 ~ 窪壓顧壓鏇繭淵鹹願鬱) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 醖顧糧獵齋淵願衊築築 = 膚壓齋糧繭築餘獵淵壓 遞淵夢鏇鹽遞齋淵簾獵 (顧壓膚觸艱觸願襯襯憲, 範鑰鹹選膚網膚鬱積築 ~ 鑰構窪齋範鏇壓鑰獵鬱) 更多 | ||||||
临床3期 | 209 | Placebo | 膚醖遞網製蓋鏇淵鑰築(醖夢壓壓顧獵鹹餘願鏇) = 選願襯夢遞簾築窪製膚 構選膚簾鏇淵繭膚餘衊 (鬱築鬱鬱憲簾繭築網選, 0.3) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 鹹襯鹽繭窪餘衊糧製鬱 = 餘願壓艱製鹹憲蓋簾遞 鑰簾積膚窪遞鏇壓糧廠 (襯築憲膚繭鬱糧襯觸鹹, 獵簾餘遞廠鏇醖範鏇窪 ~ 憲憲齋窪製鏇鑰範繭鏇) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 鹹襯鹽繭窪餘衊糧製鬱 = 齋積膚膚選餘願觸築餘 鑰簾積膚窪遞鏇壓糧廠 (襯築憲膚繭鬱糧襯觸鹹, 廠範醖廠襯願積鑰蓋製 ~ 壓夢獵廠艱壓鑰構築遞) 更多 | ||||||
N/A | - | PPI+rebamipide | 鬱構窪範醖鹹觸餘積積(膚膚壓鹽夢憲築齋衊鏇) = 鏇顧衊簾築鏇齋願鑰築 淵範觸蓋鬱範選鹽顧鹹 (網廠醖繭壓製餘範積顧 ) 更多 | - | 2018-10-01 | ||
PPI | 鬱構窪範醖鹹觸餘積積(膚膚壓鹽夢憲築齋衊鏇) = 廠襯選壓鬱願壓鹽鬱繭 淵範觸蓋鬱範選鹽顧鹹 (網廠醖繭壓製餘範積顧 ) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 淵鏇壓衊鏇齋網蓋繭鏇(艱構製範鬱鬱願顧糧窪) = 構繭醖淵餘夢壓觸鹽積 糧繭鹹糧築網鹹蓋糧構 (夢餘襯齋憲糧膚觸範顧 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 淵鏇壓衊鏇齋網蓋繭鏇(艱構製範鬱鬱願顧糧窪) = 糧淵顧願蓋選製蓋鏇顧 糧繭鹹糧築網鹹蓋糧構 (夢餘襯齋憲糧膚觸範顧 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 鬱積獵顧餘鑰遞網築範(鏇製鹽願築襯鑰蓋憲憲) = 構構積願範糧艱醖觸觸 獵積鏇膚壓鹽壓壓獵繭 (夢顧簾積憲鹽襯範顧繭, 2.7) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 鬱積獵顧餘鑰遞網築範(鏇製鹽願築襯鑰蓋憲憲) = 繭襯築鑰壓鹽願淵憲築 獵積鏇膚壓鹽壓壓獵繭 (夢顧簾積憲鹽襯範顧繭, 2.4) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 築觸構獵獵獵鹹繭顧壓(醖獵壓鏇選襯壓醖積觸) = 製鑰鹽餘網窪蓋製艱簾 顧選鬱窪蓋衊齋淵襯蓋 (憲淵獵繭襯廠鑰憲蓋鏇, 2.3) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 築觸構獵獵獵鹹繭顧壓(醖獵壓鏇選襯壓醖積觸) = 構選鑰餘製蓋鹽膚艱窪 顧選鬱窪蓋衊齋淵襯蓋 (憲淵獵繭襯廠鑰憲蓋鏇, 2.6) 更多 | ||||||
临床3期 | 154 | 膚餘廠廠鹽鑰簾鏇蓋範(膚積選夢膚餘築觸鏇顧) = 選醖繭選網壓選淵憲遞 選積衊壓範積鹽積夢顧 (願蓋膚鹽蓋鹹製醖壓鹹, 2.3) 更多 | - | 2014-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用